The Promising Future of Combination Therapies in Chronic Graft-vs-Host Disease
The medical community has celebrated a significant breakthrough in the treatment of chronic graft-versus-host disease (cGVHD) with the emergence of combination therapies. A recent retrospective study presented at the 2025 Tandem Meeting highlighted the efficacy of using axatilimab-csfr (Niktimvo) in conjunction with ruxolitinib (Jakafi) and/or belumosudil (Rezurock). The study focused on 8 heavily pretreated patients, showcasing a promising future for those grappling with this challenging ailment.
Pioneering Combination Therapies
According to the study, the combination therapy led to an overall response rate (ORR) of 25% according to National Institutes of Health (NIH) Consensus Criteria and 75% by Clinically Significant Symptomatic Improvement (CSSI) criteria. “This is the first report of axatilimab used in combination with ruxolitinib and/or belumosudil, demonstrating that combinations targeting CSF-1R, JAK2, and ROCK2 are feasible and potentially beneficial,” highlighted Jean Caputo, an expert from The Ohio State University.
Did you know? The NIH Consensus Criteria provide an objective grading scale for cGVHD, classifying disease severity as mild, moderate, or severe based on affected organs and symptoms. CSSI, on the other hand, incorporates subjective assessments, including patient-reported symptoms, offering a fuller picture of a patient’s quality of life.
Real-Life Application: The Study’s Design
The patients in the study had undergone numerous prior lines of therapy, showcasing the need for alternative treatments beyond standard care. They had received a range of treatments, including prior ruxolitinib and belumosudil, with some patients having received these in combination. When prescribed axatilimab, patients received combinations with both ruxolitinib and belumosudil, or chacne with one of the two, demonstrating diverse yet personalized treatment approaches. Despite the small sample size, the observed improvements—including reductions in sclerosis, ulcerations, and dyspnea—highlight the tangible benefits these therapies may offer.
Insights from Organ-specific Responses
Examining organ-specific responses, the therapy showed varying efficacy depending on the affected body part. Skin GVHD patients demonstrated a 15% ORR by NIH and 43% by CSSI. More encouraging results were observed in patients with oral involvement (ORR of 25% by NIH and 75% by CSSI) and lung involvement (a 50% ORR by CSSI). However, the study indicates that while CSFI was beneficial, patients experienced partial responses without achieving complete remission.
Pro tip: Measuring infections and organ-specific responses can offer personalized insights into how different organs react to combination therapies, allowing for tailored treatment strategies.
Biological Indicators: Serum Cytokines
An unexpected finding was the decrease or normalization of serum cytokines—interleukin-6, interleukin-2R, and interleukin-10—among those who responded, suggesting a reduction in inflammation and immune dysregulation. This biological metric provides a useful indicator for future studies in evaluating the efficacy of combination therapies in managing cGVHD.
Safety Profile and Adverse Events
Despite the encouraging outcomes, the study noted adverse effects, primarily manageable and dose-adjustable. Notably, there were no fatal adverse events (AEs) or discontinuations due to intolerance. This supports the therapy’s safety profile, underlining its potential viability for future applications in conjunction with other treatments.
Comparative Analysis with Prior Studies
Though the ORR was lower than that found in the AGAVE-201 trial (a 74% response rate), it is essential to consider the severity of disease in this patient group. Caputo indicated that these patients presented with more severe cGVHD, often after failing combinations of ruxolitinib and belumosudil, indicating that the combination therapy holds potential even for highly refractory cGVHD cases.
Looking Forward: The Potential Future of Combination Therapies
The encouraging findings from this study open doors to further research on the synergistic effects of combining different therapeutic agents. As medical science advances toward personalized medicine, combination therapies like these show a compelling future trend, especially for stringent cases of cGVHD that have previously posed significant treatment challenges.
Frequently Asked Questions (FAQ)
What is chronic graft-vs-host disease (cGVHD)?
cGVHD is a complex condition where immune cells from a donor’s graft attack the recipient’s body, often occurring after a bone marrow or stem cell transplant.
How does combination therapy benefit cGVHD patients?
Combination therapy offers targeted approaches, aiming to address multiple pathways of the disease, which may improve treatment response, especially in resistant cases.
Are there any risks associated with combining ruxolitinib, belumosudil, and axatilimab?
While the study reported manageable adverse events, ongoing research is crucial to fully understand and mitigate risks associated with these therapies.
Join the Conversation
Are you or a loved one dealing with cGVHD? Share your experiences or thoughts on combination therapies in the comments section below. Additionally, you can explore our in-depth guide on managing cGVHD or subscribe to our newsletter for the latest updates and treatments.
